After the rapid increase in the number of comparisons, many Chinese herbal medicines that are “high-rich” or “widely covered” have finally ushered in downward prices or low prices. It is understood that: Although it has entered the season of autumn and winter tonic, Cordyceps, Codonopsis, Panax notoginseng, the "high school, low," three grades of Chinese herbal medicines are still in the "low price" situation. “Currently including retailers and consumers have a strong wait-and-see mood, and the purchases are also small-batch, but listed companies that use these medicines as raw materials for medicines and health products are expected to decompress and benefit.” A pharmaceutical industry analyst told this reporter .

Quote: Cordyceps prices continue to fall more than 20%

Cordyceps could be said to have dominated the whole year last year, and prices of many varieties even rose by more than 40%. Since the beginning of this year, Cordyceps prices have continued to decline, and the drop has exceeded 20% so far. The reporter learned from the discovery of the Chinese herbal medicine company, Tiandi.com, although it has entered the traditional peak season, the price of Cordyceps remains at a low level. The price of 2000 Cordyceps produced in Tibet is about 195,000/kg in the wholesale market of Chinese herbal medicines in the lotus pond, which is the same as the previous collection price. Flat. Although sales of Cordyceps have improved compared to summer, due to the availability of inventory this year, the market is stable. Currently, the volume of 3100~3200 batches of the market is 13.5~138,000 yuan, and that of the dry picking operators is 14~15 million. Not so, 3,500 articles are priced from 12.5 to 30,000 yuan.

Coincidentally, the reporter found that the Codonopsis, which is highly favored by consumers, also caught up with the "low tide." According to feedback from Chinese herbal medicines, the market for Dangshen is currently stable, and the current market price for non-sulfured pieces is RMB 55. "Because this year's new goods have a lot of production, distributors all over the country are careful to start, leading to unfavorable sources of goods." A dealer in Guangzhou told this reporter, generally catch up with the price down, will be a small amount of goods in batches.

The most common three or seven of street pharmacies are no longer like the past two years. It is understood that the three quarters of this season is in the new season, Yunnan mining areas are still continuing mining, but the recent acquisition of small volume, so the market continued to decline trend. It is understood that the current market price of 120 dry goods is about 500 yuan, the new goods price is 480 yuan, and the price of 80 new dry goods is between 520 yuan and 530 yuan.

Consumption: Gifters reduce their own use of more scattered purchases "This year's Mid-Autumn Festival, the eve of National Day, Cordyceps suit sales really not as good as in previous years." A pharmacy in Guangzhou, a marketing manager told this reporter, or with "avoidance" wind blowing and so on The giver suddenly decreased. “Consumers will care more about prices and are willing to buy loose and small Cordyceps militaris. The price/performance ratio between the origin, size, and price is very important, so Tibetan production is not as popular because it is too expensive.” Indicated.

In addition, Chinese herbal medicines, including Codonopsis, Panax notoginseng, etc., are also more rational in market sales. “Before a price reduction or discount was encountered, many people would immediately pick up the goods, but now many consumers also understand the herbal medicine market and are not in a hurry to start. They wait and see the same sentiment as the dealers, and they buy batches of batches to close their positions at any time.” He said.

"If it is for personal use, Cordyceps do not need to carry the goods, because the insects are easy to mold; Codonopsis, Panax notoginseng market is now relatively stable, you can consider starting, the year should be little change in gains." Guangdong Armed Police Hospital Otolaryngology Research Center Director of Traditional Chinese Medicine Longmu Indicated.

Individual stocks investing in raw materials, low-level running listed companies continued to benefit the price of several major Chinese herbal medicines fell, many of the previous two years, "pressing" huge pharmaceutical listed companies can finally relieve their breath. Taking Cordyceps as an example, related listed companies include Furui shares (300049) and Zuoli Pharmaceutical (300181). Take Furui shares as an example. Cordyceps is the blindest raw material of the company's compound Biejia Ruangan Tablets, which accounts for more than 80% of the total cost. The price of Cordyceps is down and low, and the company will directly benefit from it; in addition, Zolli Pharmaceutical has stated in its annual report that the company's sales range includes fermented Chinese caterpillar fungus powder, so it can also achieve “throttling” from cost reduction.

The medicine rate in March 7 is very high. Most pharmaceutical listed companies will purchase 37 in varying degrees. Taking Kunming Pharmaceutical (600422) as an example, its flagship product, Xuesaitong series, is based on Panax pseudoginseng; Yunnan Baiyao (000538) is also very dependent on Panax Notoginseng, which is one of the main raw materials for various products of Yunnan Baiyao. A pharmaceutical research analyst said that because of the extensive use of Panax notoginseng and its association with numerous proprietary Chinese medicines, its price fluctuations have a very large impact, and current low-level operations can continue to benefit many listed companies.

Dong'e Ejiao (000423), Qianjin Pharmaceutical (600479), Jiuzhitang (000989) and other companies all have cosmopolitan drugs and even self-supporting planting bases. “We have more than 2,000 acres of Chinese medicine GAP base, planting two main raw materials - Codonopsis, Rehmannia, which has been certified by the GAP base. This is to start from the raw materials to protect the pharmaceutical properties, safety and high quality. "Dong Ejiao reply to this reporter said.

The analyst suggested that investors can start research on Chinese herbal medicines or celebrity drugs that they are more familiar with or are interested in, understand their main raw material market changes, price fluctuations, and product market sales and industry reputation so as to select appropriate stocks to start.